- Title
- Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study
- Creators
- Cara Mathews - University of ProvidenceJessica Thomes Pepin - Minnesota OncologyNoelle Cloven - Fondazione Ricerca TraslazionaleJustin Call - StartDebra Richardson - University of OklahomaGottfried Konecny - University of California, Los AngelesOladapo Yeku - Massachusetts General HospitalElizabeth Lee - Dana-Farber Cancer InstituteAnton Melnyk - Texas Oncology, Abilene, TX, United StatesCharles Anderson - Willamette Valley Cancer Institute and Research CenterLyndsay Willmott - Arizona Center for Cancer Care, Biltmore, Scottsdale, AZ, United Stateset al.
- Publication Details
- Gynecologic oncology, Vol.208, pp.S60-S60
- Publisher
- Elsevier Inc
- Identifiers
- 991006271510102656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study
Gynecologic oncology, Vol.208, pp.S60-S60
05/2026
Metrics
1 Record Views